Login Register Cart 0
Generic placeholder image

Current Nanomedicine

Editor-in-Chief

ISSN (Print): 2468-1873
ISSN (Online): 2468-1881

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Formulation, Optimization and Characterization of Bupropion Hydrochloride Loaded Nanostructured Lipid Carriers for Intra-Nasal Administration: An Approach to Management of Smoking Cessation

Author(s): Aravind Shyamprasad Rekharani, Bala Sai Soujith Nidamanuri, Praharsh Kumar Mandadhi Rajendra, Senthil Venkatachalam, Jubie Selvaraj and Jawahar Natarajan*

Volume 12, Issue 3, 2022

Published on: 08 November, 2022

Page: [217 - 232] Pages: 16

DOI: 10.2174/2468187313666221020143555

Price: $65

Abstract

Background: Tobacco smoking is a major factor leading to cardiovascular diseases. About 48% of cardiovascular diseases occur due to cigarette smoking. Bupropion hydrochloride is a non-nicotine treatment for smoking cessation. The existing marketed formulation of bupropion has limitations, like low bioavailability and extensive first-pass metabolism. In order to boost the bioavailability and increase the brain biodistribution of the drug, a colloidal drug delivery system, like nanostructured lipid carriers, is employed.

Methods: NLC formulation was prepared using the microemulsion technique and an optimized formula was developed using a three-level factorial design.

Results: The particle size of the optimized formulation was 162 nm, the polydispersity index was 12.2%, and the zeta potential was -29.0mV. Entrapment efficiency was found to be 41.2%. SEM images show that these NLCs are spherical. In vitro drug release study was conducted, and at the end of 72 hours, 50% of the drug was released, indicating the sustained release of the drug. Histopathological studies were conducted using goat nasal mucosa, and results indicated the NLC formulation as non-toxic for intranasal administration.

Conclusion: Thus, through the intra-nasal route, an increased concentration of drug can be delivered to the brain via the olfactory pathway, thereby improving the therapeutic effect and exhibiting better patient compliance in smoking cessation.

« Previous Next »
Graphical Abstract

[1]
Doll R. Uncovering the effects of smoking: Historical perspective. Stat Methods Med Res 1998; 7(2): 87-117.
[http://dx.doi.org/10.1177/096228029800700202] [PMID: 9654637]
[2]
Kalkhoran S, Benowitz NL, Rigotti NA. Prevention and treatment of tobacco use. J Am Coll Cardiol 2018; 72(9): 1030-45.
[http://dx.doi.org/10.1016/j.jacc.2018.06.036] [PMID: 30139432]
[3]
Carrick MA, Robson JM, Thomas C. Smoking and anaesthesia. BJA Educ 2019; 19(1): 1-6.
[http://dx.doi.org/10.1016/j.bjae.2018.09.005] [PMID: 33456847]
[4]
Wilkes S. The use of bupropion SR in cigarette smoking cessation. Int J Chron Obstruct Pulmon Dis 2008; 3(1): 45-53.
[http://dx.doi.org/10.2147/COPD.S1121] [PMID: 18488428]
[5]
Warner C, Shoaib M. How does bupropion work as a smoking cessation aid? Addict Biol 2005; 10(3): 219-31.
[http://dx.doi.org/10.1080/13556210500222670] [PMID: 16109583]
[6]
Costa R, Oliveira NG, Dinis-Oliveira RJ. Pharmacokinetic and pharmacodynamic of bupropion: Integrative overview of relevant clinical and forensic aspects. Drug Metab Rev 2019; 51(3): 293-313.
[http://dx.doi.org/10.1080/03602532.2019.1620763] [PMID: 31124380]
[7]
kaur S, Nautyal U, Singh R, Singh S, Devi A. Nanostructure Lipid Carrier (NLC): The new generation of lipid nanoparticles. Asian Pac J Health Sci 2015; 2(2): 76-93.
[http://dx.doi.org/10.21276/apjhs.2015.2.2.14]
[8]
Illum L. Nasal drug delivery: New developments and strategies. Drug Discov Today 2002; 7(23): 1184-9.
[http://dx.doi.org/10.1016/S1359-6446(02)02529-1] [PMID: 12547019]
[9]
Mittal D, Ali A, Md S, Baboota S, Sahni JK, Ali J. Insights into direct nose to brain delivery: Current status and future perspective. Drug Deliv 2014; 21(2): 75-86.
[http://dx.doi.org/10.3109/10717544.2013.838713] [PMID: 24102636]
[10]
Abo El-Enin HA, Elkomy MH, Naguib IA, et al. Lipid nanocarriers overlaid with chitosan for brain delivery of berberine via the nasal route. Pharmaceuticals 2022; 15(3): 281.
[http://dx.doi.org/10.3390/ph15030281] [PMID: 35337079]
[11]
Sharma N, Bhandari S, Deshmukh R, Yadav AK, Mishra N. Development and characterization of embelin-loaded nanolipid carriers for brain targeting. Artif Cells Nanomed Biotechnol 2017; 45(3): 409-13.
[http://dx.doi.org/10.3109/21691401.2016.1160407] [PMID: 27012597]
[12]
Costa CP, Barreiro S, Moreira JN, et al. In vitro studies on nasal formulations of nanostructured lipid carriers (NLC) and solid lipid nanoparticles (SLN). Pharmaceuticals 2021; 14(8): 711.
[http://dx.doi.org/10.3390/ph14080711] [PMID: 34451808]
[13]
Khan SR, Berendt RT, Ellison CD, Ciavarella AB, Asafu-Adjaye E, Khan MA. Chapter One - Bupropion Hydrochloride. In: Profiles of Drug Substances, Excipients and Related Methodology. Elsevier 2016; 41: pp. 1-30.
[http://dx.doi.org/10.1016/bs.podrm.2015.12.001]
[14]
Pani NR, Nath LK, Acharya S, Bhuniya B. Application of DSC, IST, and FTIR study in the compatibility testing of nateglinide with different pharmaceutical excipients. J Therm Anal Calorim 2012; 108(1): 219-26.
[http://dx.doi.org/10.1007/s10973-011-1299-x]
[15]
Salvi VR, Pawar P. Nanostructured lipid carriers (NLC) system: A novel drug targeting carrier. J Drug Deliv Sci Technol 2019; 51: 255-67.
[http://dx.doi.org/10.1016/j.jddst.2019.02.017]
[16]
Sood S, Jawahar N, Jain K, Gowthamarajan K, Nainar Meyyanathan S. Olanzapine loaded cationic solid lipid nanoparticles for improved oral bioavailability. Curr Nanosci 2013; 9: 26-34.
[17]
Zhuang CY, Li N, Wang M, et al. Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharm 2010; 394(1-2): 179-85.
[http://dx.doi.org/10.1016/j.ijpharm.2010.05.005] [PMID: 20471464]
[18]
Huang J, Wang Q, Li T, Xia N, Xia Q. Nanostructured lipid carrier (NLC) as a strategy for encapsulation of quercetin and linseed oil: Preparation and in vitro characterization studies. J Food Eng 2017; 215: 1-12.
[http://dx.doi.org/10.1016/j.jfoodeng.2017.07.002]
[19]
Swidan SA, Mansour ZN, Mourad ZA, Elhesaisy NA, Mohamed NA, Bekheet MS. DOE, formulation, and optimization of repaglinide nanostructured lipid carriers. J Anim Plant Sci 2018; 8: 8-16.
[20]
Yao Q, Yang G, Wang H, et al. Aging erythrocyte membranes as biomimetic nanometer carriers of liver-targeting chromium poisoning treatment. Drug Deliv 2021; 28(1): 1455-65.
[http://dx.doi.org/10.1080/10717544.2021.1949075] [PMID: 34236248]
[21]
Dubey A, Prabhu P, Kamath JV. Nano Structured lipid carriers: A Novel Topical drug delivery system. Int J Pharm Tech Res 2012; 4: 705-14.
[22]
Thatipamula R, Palem C, Gannu R, Mudragada S, Yamsani M. Formulation and in vitro characterization of domperidone loaded solid lipid nanoparticles and nanostructured lipid carriers. Daru 2011; 19(1): 23-32.
[PMID: 22615636]
[23]
Özbaş-Turan S, Akbuğa J. Plasmid DNA-loaded chitosan/TPP nanoparticles for topical gene delivery. Drug Deliv 2011; 18(3): 215-22.
[http://dx.doi.org/10.3109/10717544.2010.544688] [PMID: 21226549]
[24]
Brahmankar DM, Jaiswal SB. Biopharmaceutics and pharmacokinetics: A treatise. Vallabh Prakashan 2005.
[25]
Madane RG, Mahajan HS. Curcumin-loaded nanostructured lipid carriers (NLCs) for nasal administration: Design, characterization, and in vivo study. Drug Deliv 2016; 23(4): 1326-34.
[http://dx.doi.org/10.3109/10717544.2014.975382] [PMID: 25367836]
[26]
Kawtikwar PS, Kulkarni NP, Yadav S, Sakarkar DM. Formulation and evaluation of an anti-epileptic drug-loaded microemulsion for nose to brain delivery. Asian J Pharm 2014; 3.
[27]
Kumar M, Kakkar V, Mishra AK, Chuttani K, Kaur IP. Intranasal delivery of streptomycin sulfate (STRS) loaded solid lipid nanoparticles to brain and blood. Int J Pharm 2014; 461(1-2): 223-33.
[http://dx.doi.org/10.1016/j.ijpharm.2013.11.038] [PMID: 24286922]
[28]
Joshi AS, Patel HS, Belgamwar VS, Agrawal A, Tekade AR. Solid lipid nanoparticles of ondansetron HCl for intranasal delivery: Development, optimization and evaluation. J Mater Sci Mater Med 2012; 23(9): 2163-75.
[http://dx.doi.org/10.1007/s10856-012-4702-7] [PMID: 22802103]
[29]
Sood S, Jain K, Gowthamarajan K. Optimization of curcumin nanoemulsion for intranasal delivery using design of experiment and its toxicity assessment. Colloids Surf B Biointerfaces 2014; 113: 330-7.
[http://dx.doi.org/10.1016/j.colsurfb.2013.09.030] [PMID: 24121076]
[30]
Varshosaz J, Tabbakhian M, Mohammadi MY. Formulation and optimization of solid lipid nanoparticles of buspirone HCl for enhancement of its oral bioavailability. J Liposome Res 2010; 20(4): 286-96.
[http://dx.doi.org/10.3109/08982100903443065] [PMID: 19958118]
[31]
Mühlen A, Mühlen E, Niehus H, Mehnert W. Atomic force microscopy studies of solid lipid nanoparticles. Pharm Res 1996; 13(9): 1411-6.
[http://dx.doi.org/10.1023/A:1016042504830] [PMID: 8893284]
[32]
Sandri G, Bonferoni MC, Ferrari F, Rossi S, Caramella CM. The role of particle size in drug release and absorption. In: Particulate Products Particle Technology Series. Cham: Springer 2014; 19: pp. 323-41.
[33]
Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001; 13(2): 123-33.
[http://dx.doi.org/10.1016/S0928-0987(01)00095-1] [PMID: 11297896]
[34]
Ahmed S, Gull A, Alam M, Aqil M, Sultana Y. Ultrasonically tailored, chemically engineered and “QbD” enabled fabrication of agomelatine nanoemulsion; optimization, characterization, ex vivo permeation and stability study. Ultrason Sonochem 2018; 41: 213-26.
[http://dx.doi.org/10.1016/j.ultsonch.2017.09.042] [PMID: 29137746]
[35]
Seju U, Kumar A, Sawant KK. Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: In vitro and in vivo studies. Acta Biomater 2011; 7(12): 4169-76.
[http://dx.doi.org/10.1016/j.actbio.2011.07.025] [PMID: 21839863]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy